FI20071025A - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions Download PDF

Info

Publication number
FI20071025A
FI20071025A FI20071025A FI20071025A FI20071025A FI 20071025 A FI20071025 A FI 20071025A FI 20071025 A FI20071025 A FI 20071025A FI 20071025 A FI20071025 A FI 20071025A FI 20071025 A FI20071025 A FI 20071025A
Authority
FI
Finland
Prior art keywords
provides
macrolide
class
compound
pharmaceutical compositions
Prior art date
Application number
FI20071025A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI119755B (en
Inventor
Martin Jackman
Xue-Ping Popp
Richter Friedrich
Fritz Schmook
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9421612A external-priority patent/GB9421612D0/en
Priority claimed from GB9422306A external-priority patent/GB9422306D0/en
Priority claimed from GBGB9503553.1A external-priority patent/GB9503553D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of FI20071025A publication Critical patent/FI20071025A/en
Application granted granted Critical
Publication of FI119755B publication Critical patent/FI119755B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

This invention provides a topical composition, in the form of an emulsion, that comprises a compound of the FK506 class; a physiologically acceptable alkanediol, ether diol or diether alcohol containing up to 8 carbon atoms as solvent for the compound of the FK506 class; an unsaturated fatty alcohol and water. In another aspect, this invention provides a topical pharmaceutical composition that comprises a macrolide in suspension. In a further aspect, this invention provides the use of an unsaturated fatty alcohol to stabilise a macrolide in a pharmaceutical composition.
FI20071025A 1994-10-26 2007-12-28 Use of unsaturated fatty alcohol FI119755B (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB9421612A GB9421612D0 (en) 1994-10-26 1994-10-26 Organic compounds
GB9421612 1994-10-26
GB9422306A GB9422306D0 (en) 1994-11-04 1994-11-04 Organic compounds
GB9422306 1994-11-04
GB9503553 1995-02-22
GBGB9503553.1A GB9503553D0 (en) 1995-02-22 1995-02-22 Organic compounds
PCT/EP1995/004208 WO1996013249A1 (en) 1994-10-26 1995-10-26 Pharmaceutical compositions
EP9504208 1995-10-26

Publications (2)

Publication Number Publication Date
FI20071025A true FI20071025A (en) 2007-12-28
FI119755B FI119755B (en) 2009-03-13

Family

ID=27267447

Family Applications (2)

Application Number Title Priority Date Filing Date
FI971018A FI119754B (en) 1994-10-26 1997-03-11 Topical compositions
FI20071025A FI119755B (en) 1994-10-26 2007-12-28 Use of unsaturated fatty alcohol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI971018A FI119754B (en) 1994-10-26 1997-03-11 Topical compositions

Country Status (26)

Country Link
US (1) US6352998B2 (en)
EP (2) EP0786986B1 (en)
JP (3) JP4155593B2 (en)
KR (1) KR100434682B1 (en)
CN (2) CN100335063C (en)
AT (2) ATE299017T1 (en)
AU (1) AU714254B2 (en)
BR (1) BR9509530A (en)
CA (1) CA2200966C (en)
CY (1) CY2211B1 (en)
CZ (1) CZ289773B6 (en)
DE (3) DE19581804T1 (en)
DK (2) DK0786986T3 (en)
ES (2) ES2173978T3 (en)
FI (2) FI119754B (en)
GB (1) GB2308546B (en)
HK (1) HK1053611A1 (en)
HU (1) HU223840B1 (en)
MX (1) MX9702699A (en)
NO (2) NO316963B1 (en)
NZ (2) NZ295170A (en)
PL (1) PL184750B1 (en)
PT (2) PT1147766E (en)
SI (1) SI0786986T1 (en)
SK (1) SK284591B6 (en)
WO (1) WO1996013249A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR004480A1 (en) * 1995-04-06 1998-12-16 Amico Derin C D ASCOMICINE COMPOUNDS HAVING ANTI-INFLAMMATORY ACTIVITY, PROCEDURE TO PREPARE THEM, USE OF SUCH COMPOUNDS TO PREPARE PHARMACEUTICAL AGENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
CZ267796A3 (en) * 1996-09-12 1998-04-15 Galena A.S. Medicamentous preparations, particularly for internal application in the form of inherently micro-emulsifying therapeutical systems
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
TW450810B (en) * 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
DE19744621A1 (en) * 1997-10-09 1999-04-15 Muehlbauer Ernst Kg Mixture for use as a wound dressing
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
DE19802205A1 (en) * 1998-01-22 1999-07-29 Beiersdorf Ag Cosmetic or dermatological composition with electrolyte-containing aqueous phase, stable against phase separation, e.g. sunscreens
ID25908A (en) * 1998-03-06 2000-11-09 Novartis Ag EMULSION PRACTONCENTRATES CONTAINING CYCLOSPORINE OR MACROLIDES
JP3732525B2 (en) * 1998-04-27 2006-01-05 アステラス製薬株式会社 Pharmaceutical composition
GB9814640D0 (en) * 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
GB9826656D0 (en) * 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US20070032853A1 (en) * 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
GB0003932D0 (en) * 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
JP4290985B2 (en) * 2001-02-16 2009-07-08 アボット ラボラトリーズ バスキュラー エンタープライゼズ リミテッド Implant using FK506
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
AR035293A1 (en) * 2001-08-23 2004-05-05 Novartis Ag OPHTHALMIC COMPOSITION.
AR038628A1 (en) * 2002-03-04 2005-01-19 Novartis Ag OPHTHALM COMPOSITION
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
AU2004212264B9 (en) * 2003-02-17 2009-11-26 Cipla Limited Pharmaceutical patch
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307869D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
CA2533101A1 (en) * 2003-07-31 2005-02-03 Pharmacia & Upjohn Company Llc Dispersible formulation of an anti-inflammatory agent
US9168224B2 (en) * 2004-04-08 2015-10-27 Meda Pharma Sarl Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides
GB0408070D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Pharmaceutical formulations
GB0508827D0 (en) * 2005-04-29 2005-06-08 Novartis Ag Cosmeceutical composition
US9205080B2 (en) 2006-11-16 2015-12-08 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mTOR inhibitors
EP2016935A1 (en) * 2007-07-09 2009-01-21 Intendis GmbH Pharmaceutical composition for topical application of poorly soluble compounds
CN101288643B (en) * 2008-06-17 2012-11-14 杨喜鸿 Gel composition containing tacrolimu and its preparation method and medicinal application
EP2308468A1 (en) * 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
JP5674786B2 (en) * 2010-07-23 2015-02-25 マルホ株式会社 Oil-in-water cream composition containing tacrolimus
WO2012011192A1 (en) * 2010-07-23 2012-01-26 マルホ株式会社 Tacrolimus-containing oil-in-water type creamy composition
CN102552253A (en) * 2012-01-17 2012-07-11 唯美度科技（北京）有限公司 Skin external agent for eliminating acnes
JP6084579B2 (en) * 2012-01-25 2017-02-22 マルホ株式会社 Oil-in-water cream composition containing tacrolimus
ES2797376T3 (en) 2013-01-24 2020-12-02 Palvella Therapeutics Inc Compositions for the transdermal administration of mTOR inhibitors
MX367121B (en) * 2013-08-02 2019-08-06 Laboratorio Raam De Sahuayo S A De C V Stable solid composition of immunosuppressants.
DE102013222164A1 (en) * 2013-10-31 2015-04-30 Deb Ip Limited Stabilized multiple emulsions as a skin protection product
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
CN105663027B (en) * 2016-04-01 2018-12-18 中国人民解放军广州军区武汉总医院 Sirolimus external preparation, preparation method and the usage
CN109069418A (en) 2016-04-04 2018-12-21 药品配送方案有限公司 topical composition comprising tacrolimus
US10722499B2 (en) 2017-01-06 2020-07-28 Palvella Therapeutics, Inc. Anyhydrous compositions of mTOR inhibitors and methods of use
KR101973065B1 (en) 2017-09-13 2019-04-26 (주)썬테크 Wind turbine and blade tip thereof
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
KR101995905B1 (en) 2018-03-27 2019-07-04 (주)썬테크 Wind turbine and generator thereof
WO2019233722A1 (en) * 2018-06-08 2019-12-12 Almirall, S.A. Pharmaceutical composition comprising tacrolimus
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. Anhydrous compositions of mtor inhibitors and methods of use
WO2024213629A1 (en) * 2023-04-11 2024-10-17 Bausch Health Ireland Limited Topical compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299826A (en) 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
CH677448A5 (en) 1987-11-09 1991-05-31 Sandoz Ag
AU630866B2 (en) 1987-12-09 1992-11-12 Fisons Plc Macrocyclic compounds
KR0159766B1 (en) * 1989-10-16 1998-12-01 후지사와 토모키치로 Hair revitalizing agent
EP0427680B1 (en) * 1989-11-09 1995-08-23 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
US5061700A (en) 1989-11-16 1991-10-29 Gordon Jay Dow Glyceryl acetate ointment vehicles
WO1991013899A1 (en) 1990-03-12 1991-09-19 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds
WO1991019495A1 (en) 1990-06-11 1991-12-26 Fujisawa Pharmaceutical Co., Ltd. Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease
MY110418A (en) 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
SG46547A1 (en) * 1990-09-04 1998-02-20 Fujisawa Pharmaceutical Co Ointments containing tricyclic compounds
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
IE65341B1 (en) * 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
US5252732A (en) 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5208241A (en) 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
HUT66531A (en) 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
JPH06183970A (en) * 1992-12-16 1994-07-05 Fujisawa Pharmaceut Co Ltd Medicinal composition
CH686761A5 (en) * 1993-05-27 1996-06-28 Sandoz Ag Pharmaceutical formulations.
MY110603A (en) 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
ES2148345T3 (en) 1993-10-22 2000-10-16 Hexal Ag PHARMACEUTICAL COMPOSITION WITH CYCLOSPORINE A, A DERIVATIVE OF VITAMIN E AND AN EMULSIONANT.

Also Published As

Publication number Publication date
PL184750B1 (en) 2002-12-31
JP2007145860A (en) 2007-06-14
FI971018A0 (en) 1997-03-11
NO316963B1 (en) 2004-07-12
ES2243369T3 (en) 2005-12-01
ATE299017T1 (en) 2005-07-15
CZ123297A3 (en) 1997-08-13
CN1089233C (en) 2002-08-21
GB2308546A (en) 1997-07-02
EP1147766A3 (en) 2001-10-31
SK52097A3 (en) 1997-09-10
FI119755B (en) 2009-03-13
PT786986E (en) 2002-07-31
BR9509530A (en) 1997-10-14
EP0786986A1 (en) 1997-08-06
DK0786986T3 (en) 2002-04-29
AU714254B2 (en) 1999-12-23
JP2012131827A (en) 2012-07-12
CA2200966C (en) 2006-12-19
MX9702699A (en) 1997-06-28
NO971951L (en) 1997-04-25
CN1401325A (en) 2003-03-12
DE19581804T1 (en) 1998-01-22
NO2004005I2 (en) 2007-06-11
CZ289773B6 (en) 2002-04-17
KR970706796A (en) 1997-12-01
CY2211B1 (en) 2002-11-08
GB2308546B (en) 1999-06-02
HUT77140A (en) 1998-03-02
EP1147766A2 (en) 2001-10-24
JP5599422B2 (en) 2014-10-01
FI119754B (en) 2009-03-13
HU223840B1 (en) 2005-02-28
WO1996013249A1 (en) 1996-05-09
DE69525957T2 (en) 2002-11-14
ATE214593T1 (en) 2002-04-15
JP4155593B2 (en) 2008-09-24
NO971951D0 (en) 1997-04-25
NO2004005I1 (en) 2004-09-20
GB9707484D0 (en) 1997-05-28
HK1053611A1 (en) 2003-10-31
PT1147766E (en) 2005-11-30
EP1147766B1 (en) 2005-07-06
KR100434682B1 (en) 2004-08-18
DK1147766T3 (en) 2005-08-29
SI0786986T1 (en) 2002-06-30
FI971018A (en) 1997-04-18
AU3845195A (en) 1996-05-23
US20010031769A1 (en) 2001-10-18
CN100335063C (en) 2007-09-05
PL319599A1 (en) 1997-08-18
EP0786986B1 (en) 2002-03-20
DE69534306T2 (en) 2006-04-27
CN1162259A (en) 1997-10-15
ES2173978T3 (en) 2002-11-01
US6352998B2 (en) 2002-03-05
SK284591B6 (en) 2005-07-01
JPH10508588A (en) 1998-08-25
DE69525957D1 (en) 2002-04-25
NZ295170A (en) 1999-02-25
DE69534306D1 (en) 2005-08-11
NZ331824A (en) 2000-01-28
CA2200966A1 (en) 1996-05-09

Similar Documents

Publication Publication Date Title
FI20071025A (en) Pharmaceutical compositions
HUP9900925A2 (en) Sunscreen compositions
ES2074734T5 (en) USE OF COMPOSITIONS BASED ON GREAT ALCOHOLS, FOR THE PREPARATION OF EMULSIONS; PROCEDURE FOR PREPARATION OF EMULSIONS AND EMULSIONS AS GOT.
RO112987B1 (en) Pharmaceutical ointment base and pharmaceutical composition
KR890000077A (en) Deodorizing and antimicrobial compositions for use as cosmetic or topical preparations
ES2177652T3 (en) NEW FORMS OF PREPARATION OF CYCLOSPORINE FOR ORAL APPLICATION WITH SIMPLE COMPOSITION AND HIGH BIODISPONIBILITY, AND PROCEDURE FOR OBTAINING IT.
AU1076792A (en) Cosmetic composition
ES2068725T3 (en) STABLE PREPARATION CONTAINING AZELASTINE HYDROCHLORIDE.
AU2001260180A1 (en) Compositions for use as penetration promoters in transdermal formulations for highly lipophilic active ingredients
DE59002572D1 (en) OMEGA-3 FATTY ACID FAT EMULSION FOR ENDOTRACHEAL APPLICATION, THEIR PRODUCTION AND USE.
WO1995023586A3 (en) Cosmetic and/or pharmaceutical preparations
ATE160938T1 (en) SOLID ORAL PHARMACEUTICAL PREPARATION CONTAINING GEMFIBROZIL AS THE ACTIVE INGREDIENT AND METHOD FOR PRODUCTION
ATE285745T1 (en) LIPSTICKS WHICH DO NOT SWEAT THE OIL PORTION
GB9421612D0 (en) Organic compounds
UA26267C2 (en) PHARMACEUTICAL OINTMENT WHICH DOES NOT EXPRESS IMPACT TO THE SKIN

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 119755

Country of ref document: FI

MM Patent lapsed
SPCL Withdrawal, rejection or dismissal of a supplementary protection certificate

Spc suppl protection certif: C20090029

MA Patent expired